Moffitt logo

COVID-19 Update: See the latest on our visitor policy here. Learn More

Clinical Trials Search

Clinical Trial 21082

Cancer Type: Genitourinary
Study Type: Treatment
NCT#: NCT04647526

Phase: Phase III
Principal Investigator: El-Haddad, Ghassan

Call 813-745-6100
or 1-800-679-0775 Learn More

Study Title

SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment


The purpose of this study is to evaluate the efficacy and safety of [Lu-177]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT).


Primary Objective: * To determine the efficacy of 177Lu- PNT2002 versus abiraterone or enzalutamide in delaying radiographic progression in patients with mCRPC who have progressed on ARAT. Secondary Objectives: * To assess the radiographic response to 177Lu-PNT2002 versus abiraterone or enzalutamide. * To determine the effect of 177 Lu-PNT2002 versus abiraterone or enzalutamide on overall survival in patients who have progressed on ARAT. * To determine the effect of 177Lu-PNT2002 versus abiraterone or enzalutamide on PSA kinetics in patients who have progressed on ARAT.



Hormonal Therapy; Immunotherapy; Therapy (NOS)


177Lu-PNT2002 (); Abiraterone acetate (); Enzalutamide (Xtandi); Zytiga (Abiraterone acetate)

Inclusion Criteria

Inclusion Criteria:

  • Male aged 18 years or older.
  • Histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate.
  • Ineligible or averse to chemotherapeutic treatment options.
  • Patients must have progressive mCRPC at the time of consent based on at least 1 of the following criteria: (a) Serum/plasma PSA progression defined as increase in PSA greater than 25% and >2 ng/mL above nadir, confirmed by progression at 2 time points at least 3 weeks apart. (b) Soft-tissue progression defined as an increase >20% in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or a new lesion. (c) Progression of bone disease: defined as the appearance of two or more new lesions by bone scan.
  • Previous treatment with one ARAT (abiraterone or enzalutamide or darolutamide or apalutamide) in either the CSPC or CRPC setting.
  • PSMA-PET scan (i.e., 68Ga-PSMA-11 or 18F-DCFPyL) positive as determined by the sponsor's central reader.
  • Castrate circulating testosterone levels (> Adequate organ function, independent of transfusion, as defined in protocol.
  • Human immunodeficiency virus-infected patients who are healthy and have a low risk of acquired immunodeficiency syndrome-related outcomes are included in this trial.
  • For patients who have partners who are pregnant or of childbearing potential: a condom is required along with a highly effective contraceptive method during the study and for 6 months after last study drug administration. Such methods deemed highly effective include a) combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, b) progestogen-only hormonal contraception associated with inhibition of ovulation, c) intrauterine device (IUD), d) intrauterine hormone-releasing system (IUS), e) bilateral tubal occlusion, f) vasectomy, g) true sexual abstinence: when this is in line with the preferred and usual lifestyle of the subject [periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of exposure to IMP, and withdrawal are not acceptable methods of abstinence].
  • Willing to initiate ARAT therapy (either enzalutamide or abiraterone), pre-specified by investigator, if randomized to Treatment Arm B.
  • ECOG performance status 0 to 1.
  • Willing and able to comply with all study requirements and treatments (including 177Lu PNT2002) as well as the timing and nature of required assessments.
  • Signed informed consent.

  • Exclusion Criteria

    Exclusion Criteria:

  • Prostate cancer with known significant (>10%) sarcomatoid or spindle cell or neuroendocrine components. Any small cell component in the cancer should result in exclusion.
  • Prior treatment for prostate cancer > Any prior cytotoxic chemotherapy for CRPC (e.g., cabazitaxel or docetaxel); chemotherapy for hormone-sensitive prostate cancer (HSPC) is allowed if the last dose was administered >1 year prior to consent.
  • Prior treatment with systemic radionuclides (e.g. radium-223, rhenium-186, strontium 89).
  • Prior immuno-therapy, except for sipuleucel-T.
  • Prior PSMA-targeted radioligand therapy, e.g., Lu-177-PSMA-617, I 131-1095.
  • Prior poly ADP ribose polymerase (PARP) inhibitor for prostate cancer.
  • Patients who have had 2 or more lines of ARATs.
  • Patients receiving bone-targeted therapy (e.g. denosumab, zoledronic acid) not on stable doses for at least 4 weeks prior to randomization.
  • Administration of an investigational agent > Major surgery > Estimated life expectancy > Presence of liver metastases >1 cm on abdominal imaging.
  • A superscan on bone scan defined as a bone scan that demonstrates markedly increased skeletal radioisotope uptake relative to soft tissues in association with absent or faint genitourinary tract activity71.
  • Dose escalation or initiation of opioids for cancer-related pain > Known presence of central nervous system metastases.
  • Contraindications to the use of planned ARAT therapy.
  • Active malignancy other than low-grade non-muscle-invasive bladder cancer and non melanoma skin cancer.
  • Concurrent illness that may jeopardize the patient's ability to undergo study procedures.
  • Serious psychological, familial, sociological, or geographical condition that might hamper compliance with the study protocol and follow-up schedule. Patients that travel need to be capable of repeated visits even if they are on the control arm.
  • Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression.
  • Concurrent serious (as determined by the investigator) medical conditions, including, but not limited to, New York Heart Association class III or IV congestive heart failure (see 12.1 Appendix 1), unstable ischemia, uncontrolled symptomatic arrhythmia, history of congenital prolonged QT syndrome, uncontrolled infection, known active hepatitis B or C, or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation.

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.